Analysts expect Walgreens Boots Alliance Inc (NASDAQ:WBA) to announce sales of $33.56 billion for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have made estimates for Walgreens Boots Alliance’s earnings, with the lowest sales estimate coming in at $31.34 billion and the highest estimate coming in at $34.86 billion. Walgreens Boots Alliance posted sales of $30.12 billion in the same quarter last year, which suggests a positive year over year growth rate of 11.4%. The business is scheduled to issue its next quarterly earnings report on Thursday, July 5th.
On average, analysts expect that Walgreens Boots Alliance will report full year sales of $130.67 billion for the current financial year, with estimates ranging from $124.02 billion to $133.29 billion. For the next year, analysts forecast that the firm will post sales of $137.87 billion per share, with estimates ranging from $127.51 billion to $141.63 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Walgreens Boots Alliance.
Walgreens Boots Alliance (NASDAQ:WBA) last announced its quarterly earnings results on Wednesday, March 28th. The pharmacy operator reported $1.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.18. The company had revenue of $33.02 billion during the quarter, compared to analyst estimates of $32.20 billion. Walgreens Boots Alliance had a net margin of 3.33% and a return on equity of 20.38%. The firm’s revenue was up 12.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.36 EPS.
A number of brokerages have recently issued reports on WBA. BidaskClub cut shares of Walgreens Boots Alliance from a “hold” rating to a “sell” rating in a report on Tuesday, April 10th. Zacks Investment Research raised shares of Walgreens Boots Alliance from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a report on Saturday, April 7th. Jefferies Group set a $85.00 target price on shares of Walgreens Boots Alliance and gave the company a “buy” rating in a report on Tuesday, April 3rd. Scotiabank dropped their target price on shares of Walgreens Boots Alliance from $93.00 to $91.00 and set an “outperform” rating on the stock in a report on Monday, April 2nd. Finally, Pivotal Research set a $70.00 target price on shares of Walgreens Boots Alliance and gave the company a “hold” rating in a report on Thursday, March 29th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $83.20.
WBA traded down $1.22 during trading on Monday, hitting $65.04. The company had a trading volume of 1,589,607 shares, compared to its average volume of 5,833,745. The stock has a market capitalization of $65,420.18, a P/E ratio of 12.75, a P/E/G ratio of 1.07 and a beta of 1.16. Walgreens Boots Alliance has a one year low of $61.74 and a one year high of $87.79. The company has a current ratio of 0.90, a quick ratio of 0.45 and a debt-to-equity ratio of 0.44.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Investors of record on Friday, May 18th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, May 17th. This represents a $1.60 annualized dividend and a dividend yield of 2.46%. Walgreens Boots Alliance’s dividend payout ratio is 31.37%.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership lifted its stake in Walgreens Boots Alliance by 675.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,891,845 shares of the pharmacy operator’s stock valued at $427,866,000 after purchasing an additional 5,132,140 shares during the last quarter. LSV Asset Management lifted its stake in Walgreens Boots Alliance by 38,624.0% in the 4th quarter. LSV Asset Management now owns 3,678,780 shares of the pharmacy operator’s stock valued at $267,153,000 after purchasing an additional 3,669,280 shares during the last quarter. Two Sigma Advisers LP lifted its stake in Walgreens Boots Alliance by 315.6% in the 4th quarter. Two Sigma Advisers LP now owns 2,639,155 shares of the pharmacy operator’s stock valued at $191,655,000 after purchasing an additional 2,004,131 shares during the last quarter. CI Global Investments Inc. lifted its stake in Walgreens Boots Alliance by 32.0% in the 4th quarter. CI Global Investments Inc. now owns 7,373,589 shares of the pharmacy operator’s stock valued at $535,470,000 after purchasing an additional 1,785,449 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its stake in Walgreens Boots Alliance by 875.2% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,650,553 shares of the pharmacy operator’s stock valued at $119,862,000 after purchasing an additional 1,481,305 shares during the last quarter. Institutional investors and hedge funds own 60.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Walgreens Boots Alliance Inc (WBA) Expected to Announce Quarterly Sales of $33.56 Billion” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://ledgergazette.com/2018/04/19/walgreens-boots-alliance-inc-wba-expected-to-announce-quarterly-sales-of-33-56-billion.html.
About Walgreens Boots Alliance
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.